新版诊疗难治性狼疮肾炎单药多靶点与多药多靶点
*仅供医学专业人士阅读参考
面对善于乔装的“狼外婆”,探索更多潜在治疗方案才能更好地识破它、捕获它。
新版诊疗规范发布,
挑战与机遇并存
LN治疗目标是减少尿蛋白、保护肾脏、阻止或延缓肾功能恶化和改善患者预后;
激素和羟氯喹仍是LN治疗的基础用药,而免疫抑制剂的使用应根据疾病病理类型、病理活动性并结合肾外病变来选择;
若常规治疗疗效不佳,可采用激素联合钙调神经磷酸酶抑制剂或多靶点方案。其中,多靶点方案可用于诱导治疗,亦可用于维持治疗;
目前LN维持治疗的趋势是尽可能使用更低剂量的激素。
团队作战,
多靶点方案或在LN中更具优势
参考文献:
[1]张辉,杨念生,鲁静,等.狼疮肾炎诊疗规范[J].中华内科杂志,2020,60(9):784-790.
[2]Rovin BH, Caster DJ, Cattran DC, et al.Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J].Kidney Int, 2019,95(2):281-295.
[3]Fanouriakis A,Kostopoulou M,Cheema K,et al.2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA)recommendations for the management of lupus nephritis[J].Ann Rheum Dis,2020,79(6):713-723.
[4]CSTAR.系统性红斑狼疮发展报告2019.
[5]关天俊.狼疮性肾炎多靶点治疗的疗效优势[J].内科急危重症杂志,2015,21(4):245-247.
[6]鲍浩,章海涛,张馨,等.难治性狼疮性肾炎多靶点治疗前瞻性临床研究[J].肾脏病与透析肾移植杂志,2007,16(1):5-13.
[7]Bao H,Liu ZH,Xie HL,et al.Successful treatment of class IV V lupus nephritis with muItitarget therapy[J].J Am Soc Nephrol,2008,17(10):2001-2010.
[8]鲍浩,刘志红,胡伟新,等.多靶点诱导治疗增殖性和膜性狼疮性肾炎前瞻对照性临床研究[J].肾脏病与透析肾移植杂志,2009,18(3):201-206.
[9]许圣淳,陈樱花,刘正钊,等.多靶点治疗V IV型狼疮性肾炎的长期随访[J].肾脏病与透析肾移植杂志,2012,21(2):101-108.
[10]钱文麒,韩伟,唐三植,等.多靶点药物的开发策略及研究[J].广东化工,2014,41(8):69-72.
[11]Y Xu,Q Zhu,J.Song,et al. Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis[J]. Mediators Inflamm, 2015,356040.
[12]C Lina,W Conghua,L Nan,et al. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis[J]. Clin Immunol,2011,31(4): 596-605.
[13]Yan Y,Mei L,Q FuYe,et al. Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis[J]. Arthritis Research&Therapy, 2019,21:92.
[14]Luo Q,Sun Y,Liu W,et al.A novel disease-modifying antirheumatic drug,iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide[J].The Journal of Immunology, 2013,191(10), 4969–4978.
[15]M Kohno,Y Aikawa,Y Tsubouchi,et al.Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells[J].Journal of Rheumatology.2001,28(12):2591-6.
[16]Xia Y,Fang X,Dai X,et al. Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus[J]. Int Immunopharmacol, 2021,96:107563.
[17]Yan Q,Du F,Huang X,et al.Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice[J].PLoS One,2014,9(10):e108273.
[18]Kang Y,Yan Q,Fu Q,et al. Iguratimod as an alternative induction therapy for refractory lupus nephritis:a preliminary investigational study[J]. Arthritis Res Ther,2020,22(1):65.
[19]Yan Q,Du F,Kang Y,et al.Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis:study protocol for a multi-center,randomized,controlled clinical trial(iGeLU study)[J].Trials.2021,22(1):530.
此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场。